Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells

International Journal of Oncology

Volumn 12, Issue 2, 1998, Pages 315-319

  Fardel, Olivier ^a   Payen, Léa ^a   Courtois, Arnaud ^a   Drenou, Bernard ^b   Fauchet, Renée ^b   Rault, Bernard ^a  

^a INSERM   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Anticancer drug; CD34+ acute myeloid leukemias; Drug efflux; Multidrug resistance associated protein; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; DAUNORUBICIN; GLYCOPROTEIN P; PROBENECID; TRITIUM; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031933279     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.2.315     Document Type: Article

References (30)

1. Rohatiner A and Lister TA: Acute myelogenous leukemia in adults. In: Leukemia. Henderson ES, Lister TA and Greaves MF (eds). W.B. Saunders Company, Philadelphia, pp479-507, 1996.
2. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S and Civin CI: Prognostic importance of immuno-phenotyping in adults with acute myelocytic leukemia. The significance of the stem-cell glycoprotein CD34 (MY.10). Br J Haematol 76: 340-347, 1990.
3. Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CK, Forrest A and Schiffer CA: The significance of CD34 expression in patients with untreated de novo acute myeloid leukemia. Leukemia 16: 1203-1209, 1992.
4. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D and Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79: 473-476, 1992.
5. Gottesman MM and Pastan I: Biochemistry of MDR mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
6. Bellamy WT and Dalton WS: Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31: 1-61, 1994.
7. Fardel O, Lecureur V and Guillouzo A: The P-glycoprotein multidrug transporter. Gen Pharmacol 27: 1283-1291, 1996.
8. Chaudhary PM and Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94, 1991.
9. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215-2222, 1993.
10. + acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 82: 3445-3451, 1993.
11. + acute myeloid leukemia cells. Blood 82: 3157-3162, 1993.
12. + cells. Leuk Res 17: 1031-1035, 1993.
13. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R and Le Prisé P-Y: Multidrug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 9: 1549-1555, 1995.
14. - cases. Blood 86: 2329-2342, 1995.
15. Lautier D, Canitrot Y, Deeley RG and Cole SPC: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
16. Twentyman PR, Rhodes T and Rayner S: A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30A: 1360-1369, 1994.
17. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S and Fojo T: Generation of a drug resistance profile by quantitation of mdr1/r1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 95: 2205-2214, 1995.
18. Morimoto K, Robin E, Le Bousse-Kerdiles MC, Li Y, Clay D, Jasmin C and Smadja-Joffe F: CD44 mediates hyaluronan binding by human myeloid KG1a and KG1 cells. Blood 83: 657-662, 1994.
19. - cell lines for use as reagents in flow cytometry of hematopoietic progenitor cells. Transfusion 36: 985-988, 1996.
20. Zijlstra JG, De Vries EGE and Mulder NH: Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780-1784, 1987.
21. Carmichael J, De Graff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
22. 2(S) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 25: 14-20, 1996.
23. Feller N, Broxterman HJ, Währer DCR and Pinedo HM: ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 368: 385-388, 1995.
24. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, von Hoff DD and Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymcrase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164, 1990.
25. Damon M, Fautrel A, Guillouzo A and Corcos L: Genetic analysis of the phenobarbital regulation of the cytochrome P-450 2b9 and aldehyde dehydrogenase type 2 mRNAs in mouse liver. Biochem J 317: 481-486, 1996.
26. Bailly JD, Muller C, Jaffrezou JP, Demur C, Cassar G, Bordier C and Laurent G: Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9: 799-807, 1995.
27. Legrand O, Perrot JY, Tang RP, Simonin G, Gurbuxani S, Zittoun R and Marie JP: Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haematopoietic cells. Br J Haematol 94: 23-33, 1996.
28. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ and Kaufman SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186-193, 1995.
29. Baggetto LG: Non P-glycoprotein novel proteins involved in human cancer multidrug resistance. Bull Cancer 84: 385-390, 1997.
30. Lautier D, Bailly JD, Demur C, Herbert JM, Bousquet C and Laurent G: Altered intracellular distribution of daunorubicin in immature myeloid leukemia cells. Int J Cancer 71: 292-299, 1997.